Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy U Lin

Showing results (181-190 of 330) with videos related to

Pageof 33
Sort By:
Nature Reviews. Clinical Oncology|April 21, 2023
Understanding the activity of antibody-drug conjugates in primary and secondary brain tumoursMaximilian J Mair, Rupert Bartsch, Emilie Le Rhun, et al.
The Oncologist|May 20, 2023
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and ControversiesStefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Breast Cancer Research and Treatment|July 24, 2021
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancerSara M Balch, Ines Vaz-Luis, Tianyu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2021
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Breast Cancer Research and Treatment|March 7, 2026
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasisAntonio Giordano, Noah Graham, Ayal A Aizer, et al.
Journal of the National Cancer Institute|August 14, 2025
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancerPaolo Tarantino, Do Lee, Julia Foldi, et al.
Breast Cancer Research and Treatment|March 16, 2012
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabNancy U Lin, Eric P Winer, Duncan Wheatley, et al.
Journal of Neuro-Oncology|June 8, 2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancerRachna Malani, Martin Fleisher, Priya Kumthekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2022
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline UpdateNaren Ramakrishna, Carey K Anders, Nancy U Lin, et al.
Pageof 33

Showing results (181-190 of 330) with videos related to

Sort By:
Pageof 33
Nature Reviews. Clinical Oncology|April 21, 2023
Understanding the activity of antibody-drug conjugates in primary and secondary brain tumoursMaximilian J Mair, Rupert Bartsch, Emilie Le Rhun, et al.
The Oncologist|May 20, 2023
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and ControversiesStefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Breast Cancer Research and Treatment|July 24, 2021
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancerSara M Balch, Ines Vaz-Luis, Tianyu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2021
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Breast Cancer Research and Treatment|March 7, 2026
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasisAntonio Giordano, Noah Graham, Ayal A Aizer, et al.
Journal of the National Cancer Institute|August 14, 2025
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancerPaolo Tarantino, Do Lee, Julia Foldi, et al.
Breast Cancer Research and Treatment|March 16, 2012
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabNancy U Lin, Eric P Winer, Duncan Wheatley, et al.
Journal of Neuro-Oncology|June 8, 2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancerRachna Malani, Martin Fleisher, Priya Kumthekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2022
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline UpdateNaren Ramakrishna, Carey K Anders, Nancy U Lin, et al.
Pageof 33